Webster Stephen W 4

What Happened Stephen W. Webster, a director of NextCure, Inc. (NXTC), was granted a derivative award for 2,340 shares on June 18, 2026. The filing reports an acquisition (transaction code A) of 2,340 shares at $0.00 (no cash paid). The award is recorded as a derivative instrument (an option/award) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-18. Form filed: 2026-06-22 (timely filing).
• Transaction type: A = Award/Grant (derivative); reported price $0.00; total cash paid $0.
• Shares granted: 2,340 derivative shares (option/award).
• Vesting: Per footnote, the option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Filing status: Filed within required reporting window (no late filing flagged).

Context This was a compensation-related award (grant of a derivative interest) rather than an outright purchase or sale. Such grants are common for directors and reflect equity compensation subject to vesting; they do not necessarily signal immediate buying or selling intent. Because the award vests later, there was no immediate sale or cash exercise reported.